Labcorp Growth Push Meets Cost and Reimbursement Risks

Labcorp shares have risen 23.4% year to date, as the diagnostics company expands specialty and consumer testing. Zacks Equity Research said growth initiatives are helping the business, but cost pressures and reimbursement changes pose risks.

The research points to double-digit revenue growth in specialty areas including oncology, women’s health, autoimmune disease and neurology during the first half of 2026. Labcorp also reported double-digit growth in its consumer business, supported by its testing services and new at-home options.

Acquisitions and contracts are adding to the company’s reach. In the second quarter, Labcorp completed acquisitions of select Parkview Health outreach laboratory services and Tribal Diagnostics, and secured a Department of Defense testing contract. Net acquisitions contributed 1.2% to enterprise revenue growth and 1.9% to Diagnostics growth during the quarter, according to the article.

Margins also improved. Enterprise adjusted operating margin rose 70 basis points year over year to 15.8% in the second quarter. Management expects full-year 2026 margins to improve across the enterprise, Diagnostics and BLS.

The risks include higher costs and possible pressure on testing demand. Cost of revenues increased 5.6% year over year in the second quarter. Management estimated that Affordable Care Act-related changes reduced diagnostic volume by 20 to 30 basis points in the quarter, and assumed a 30-basis-point impact for the full year.

The Zacks consensus estimate for 2026 earnings per share increased 0.2% over the past 30 days to $18.32. Its revenue estimate stands at $14.75 billion, which the article says implies 5.7% growth from 2025.